Efficacy and safety of liraglutide in patients with type 2 diabetes mellitus and severe obstructive sleep apnea

被引:0
作者
Wenlong Jiang
Weiguo Li
Jing Cheng
Wen Li
Fangzhou Cheng
机构
[1] Shenzhen Yantian District People’s Hospital,Department of Cardiovascular
[2] Longyan First Hospital Affiliated to Fujian Medical University,Department of Cardiovascular
来源
Sleep and Breathing | 2023年 / 27卷
关键词
Liraglutide; 2 diabetes mellitus; Apnea–hypopnea index; Obstructive sleep apnea; Body mass index;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1687 / 1694
页数:7
相关论文
共 79 条
[1]  
Devaraj NK(2020)Knowledge, attitude, and practice regarding obstructive sleep apnea among primary care physicians Sleep and Breathing 24 1581-1590
[2]  
Coughlin SR(2004)Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome Eur Heart J 25 735-741
[3]  
Mawdsley L(2009)Obstructive sleep apnea among obese patients with type 2 diabetes Diabetes Care 32 1017-1019
[4]  
Mugarza JA(2006)Prevalence of obstructive sleep apnoea in men with type 2 diabetes Thorax 61 945-950
[5]  
Foster GD(2018)A population-based study of the bidirectional association between obstructive sleep apnea and type 2 diabetes in three prospective US cohorts Diabetes Care 41 2111-9
[6]  
Sanders MH(2009)A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: the sleep ahead study Arch Intern Med 169 1619-1626
[7]  
Millman R(2012)Metabolic surgery and obstructive sleep apnoea: the protective effects of bariatric procedures Thorax 67 442-449
[8]  
West SD(2012)Continuous positive airway pressure improves sleepiness but not calculated vascular risk in patients with minimally symptomatic obstructive sleep apnoea: the mosaic randomised controlled trial Thorax 67 1090-1096
[9]  
Nicoll DJ(2015)Effects of CPAP on body weight in patients with obstructive sleep apnoea: a meta-analysis of randomised trials Thorax 70 258-264
[10]  
Stradling JR(2013)Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study Lancet 381 117-124